{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:51:47Z","timestamp":1776952307461,"version":"3.51.4"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The leucine-rich glioma-inactivated protein 1 (LGI1) antibody-related autoimmune encephalitis can occur alone or in the setting of a malignancy and manifest with faciobrachial dystonic seizures (FBDS), cognitive decline, hyponatremia, and neuropsychiatric disorders. The importance of differentiating this entity from acute delirium cannot be overemphasized.<\/jats:p>\n               <jats:p>This review provides a detailed account of a 71-year-old man with previous diagnosis of lung cancer who presented with subacute onset behavioural changes, urinary retention, and FBDS. Investigation revealed hyponatremia, bilateral mesial temporal lobe high signal abnormality worse on the right on MRI and CSF positive anti-LGI1 antibodies (1:30). The patient was treated with immunosuppressive therapy with consequent symptom improvement.<\/jats:p>\n               <jats:p>This case emphasizes the need to have a high index of suspicion for this disease entity in patients presenting with new onset behavioural changes and the importance of identifying the typical FBDS, as early initiation of treatment confers a positive outcome for diseased patients.<\/jats:p>","DOI":"10.1093\/omcr\/omae171","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T09:11:14Z","timestamp":1735463474000},"source":"Crossref","is-referenced-by-count":2,"title":["LGI1 encephalitis manifesting as a delayed paraneoplastic response of squamous cell lung cancer on remission"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5058-1955","authenticated-orcid":false,"given":"Ikechukwu","family":"Chukwuocha","sequence":"first","affiliation":[{"name":"Department of Neurology, New Cross Hospital, Royal Wolverhampton NHS Trust , Wolverhampton Road, Heath Town, West Midlands, WV10 0QP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baig","family":"Al-Moyeed","sequence":"additional","affiliation":[{"name":"Department of Neurology, New Cross Hospital, Royal Wolverhampton NHS Trust , Wolverhampton Road, Heath Town, West Midlands, WV10 0QP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Eigbe","sequence":"additional","affiliation":[{"name":"Department of Neurology, New Cross Hospital, Royal Wolverhampton NHS Trust , Wolverhampton Road, Heath Town, West Midlands, WV10 0QP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpi","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Neurology, New Cross Hospital, Royal Wolverhampton NHS Trust , Wolverhampton Road, Heath Town, West Midlands, WV10 0QP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"2024122909110331100_ref1","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Clinical syndrome and long-term follow-up","volume":"87","author":"Van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2024122909110331100_ref2","doi-asserted-by":"publisher","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"key":"2024122909110331100_ref3","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"key":"2024122909110331100_ref4","doi-asserted-by":"publisher","first-page":"e905","DOI":"10.1212\/NXI.0000000000000905","article-title":"LGI1 encephalitis with squamous lung-cell carcinoma: resolution after tumor resection","volume":"8","author":"Virupakshaiah","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024122909110331100_ref5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"Van Sonderen","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2024122909110331100_ref6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12883-023-03299-z","article-title":"Clinical characteristics of leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 6-year-old girl: case report and literature reviews","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Neurol"},{"key":"2024122909110331100_ref7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aian.AIAN_377_18","article-title":"Leucine-rich glioma-inactivated protein 1 antibody-positive limbic encephalitis in a patient with adenocarcinoma of prostate: a case report","volume":"22","author":"Navalli","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"2024122909110331100_ref8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","article-title":"Encephalitis and antibodies to synaptic and neuronal cell surface proteins","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"key":"2024122909110331100_ref9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11910-007-0053-z","article-title":"The neurobiology of epilepsy","volume":"7","author":"Scharfman","year":"2007","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2024122909110331100_ref10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.oraloncology.2007.10.011","article-title":"CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma--a pilot study","volume":"44","author":"Fialka","year":"2008","journal-title":"Oral Oncol"},{"key":"2024122909110331100_ref11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"2024122909110331100_ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3988\/jcn.2016.12.1.1","article-title":"The diagnosis and treatment of autoimmune encephalitis","volume":"12","author":"Lancaster","year":"2016","journal-title":"J Clin Neurol"},{"key":"2024122909110331100_ref13","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1212\/NXI.0000000000000161","article-title":"Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures","volume":"2","author":"Flanagan","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024122909110331100_ref14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/WNL.0b013e3182152808","article-title":"Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?","volume":"76","author":"Andrade","year":"2011","journal-title":"Neurology"},{"key":"2024122909110331100_ref15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"2024122909110331100_ref16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40265-022-01826-9","article-title":"Immune mechanisms in Epileptogenesis: update on diagnosis and treatment of autoimmune epilepsy syndromes","volume":"83","author":"Flammer","year":"2023","journal-title":"Drugs"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2024\/12\/omae171\/61290386\/omae171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2024\/12\/omae171\/61290386\/omae171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T09:11:16Z","timestamp":1735463476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omae171\/7934135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omae171","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,12]]},"article-number":"omae171"}}